Schering Board Accepts Bayer Offer; Private Equity Firms Eye Bayer Units

Alperowicz, Natasha
April 2006
Chemical Week;4/5/2006, Vol. 168 Issue 12, p18
Trade Publication
The article reports on the recommendations by the supervisory board of Schering that shareholders accept a takeover offer from Bayer as of March 29, 2006. The deal will increase Bayer's health care sales, making it the 12th-largest health-care group, compared with its current rank of about 20. The business will account for almost 50 percent of Bayer group sales, compared with the current 36 percent and will be by far the largest of Bayer's three manufacturing subgroups, which also include Bayer MaterialScience, and Bayer CropScience.


Related Articles

  • Schering shareholders fight on. Gibson, Jane // ICIS Chemical Business;1/22/2007, Vol. 2 Issue 50, p8 

    The article reports that with a 96.2% majority, Bayer easily squeezed out the remaining Schering shareholders at an extraordinary general meeting. But some, unhappy with the size of the last offered €98.98/share pay out, vowed to sue for higher compensation. A representative of the...

  • Bayer Schering job cuts. Williams, Dede // ICIS Chemical Business;3/5/2007, Vol. 2 Issue 56, p13 

    The article reports on job cuts at Bayer and Schering. The author states that Schering is set to cut 950 jobs at its former headquarters in Berlin, Germany. The author added that this is due to the merger between the pharmaceutical activities of Schering and Bayer. In relation to this, Bayer...

  • Bayer Clinches Acquisition of Schering.  // Chemical Week;6/28/2006, Vol. 168 Issue 22, p5 

    The article reports on the acquisition of Schering by Bayer as of June 28, 2006. Shareholders representing majority of Schering's equity had accepted Bayer's offer by June 20. Bayer will merge its pharmaceuticals business with Schering to form Bayer Schering Pharma in Berlin, Germany. Its...

  • Sale of Merck's Shares Paves Way for Bayer to Buy Schering. Young, Ian // Chemical Week;6/21/2006, Vol. 168 Issue 21, p8 

    The article reports on the agreement of Merck KGaA to sell its stake in Schering to Bayer. The agreement means that Bayer will have to pay almost €17 billion for Schering, compared with the €16.5 billion it had originally offered. Bayer also announced that it had filed a lawsuit in...

  • Bayer Sees Slow Growth; Targets Higher Pharma Rank. Alperowicz, Natasha // Chemical Week;2/27/2012, Vol. 174 Issue 7, p14 

    The article offers information on the fourth quarter report of Bayer AG. It mentions that HealthCare and CropScience, two subgroups of Bayer has achieved modest sales gain on a currency and portfolio adjusted basis. It further presents several guidelines for the subgroups of Bayer including...

  • Too little, too late? Abbot, Alison // Nature;3/30/2006, Vol. 440 Issue 7084, p603 

    The article examines the merger activity in the pharmaceutical industry in Germany. It details Bayer AG's offer to buy Schering AG. According to pharmaceutical analysts, the merger will affect mid-sized drug companies. There are three ways for these companies to respond according to a report...

  • Bayer Makes Schering Offer Official; Schering Recommends Bid.  // Chemical Week;4/26/2006, Vol. 168 Issue 14, p5 

    The article reports on the official bid price for the acquisition of Schering released by Bayer in April 2006. According to Bayer, there is approximately €3 billion in liquidity available to finance the acquisition. The acquisition would increase the sales of Bayer that were generated by...

  • Bayer Wins Schering. S. H. // Pharmaceutical Executive;Aug2006, Vol. 26 Issue 8, p30 

    The article reports that Bayer AG has acquired the Schering AG. After a long battle with Merck KGaA, the company finally secures enough cash to buy out the share of Merck. Merck had entered into a hostile bid for Schering, but its offer was rejected in favor of Bayer's counterbid. Bayer's bid...

  • Bayer Nears Deal to Purchase Aventis CropScience Joint Venture.  // Chemical Market Reporter;9/10/2001, Vol. 260 Issue 10, p5 

    Reports that Bayer AG is close to reaching an agreement with Aventis and Schering AG for the acquisition of their Aventis CropScience joint venture. Regulations of France on takeovers; Value of the agreement; Investigation of German prosecutors on complaints filed by German patients about...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics